Answers are grounded in this paper and cite their sources.
Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.
No takes yet. Share an insight, caveat, or question.
Kwa et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: